447 related articles for article (PubMed ID: 22689675)
1. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Usmani SZ; Heuck C; Mitchell A; Szymonifka J; Nair B; Hoering A; Alsayed Y; Waheed S; Haider S; Restrepo A; Van Rhee F; Crowley J; Barlogie B
Haematologica; 2012 Nov; 97(11):1761-7. PubMed ID: 22689675
[TBL] [Abstract][Full Text] [Related]
2. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.
Pour L; Sevcikova S; Greslikova H; Kupska R; Majkova P; Zahradova L; Sandecka V; Adam Z; Krejci M; Kuglik P; Hajek R
Haematologica; 2014 Feb; 99(2):360-4. PubMed ID: 24038024
[TBL] [Abstract][Full Text] [Related]
3. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
Tirumani SH; Sakellis C; Jacene H; Shinagare AB; Munshi NC; Ramaiya NH; Van den Abbeele AD
Clin Nucl Med; 2016 Jan; 41(1):e7-13. PubMed ID: 26252323
[TBL] [Abstract][Full Text] [Related]
4. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
5. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
6. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
Beksac M; Seval GC; Kanellias N; Coriu D; Rosiñol L; Ozet G; Goranova-Marinova V; Unal A; Bila J; Ozsan H; Ivanaj A; Balić LI; Kastritis E; Bladé J; Dimopoulos MA
Haematologica; 2020 Jan; 105(1):201-208. PubMed ID: 31278209
[TBL] [Abstract][Full Text] [Related]
7. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.
Rasche L; Röllig C; Stuhler G; Danhof S; Mielke S; Grigoleit GU; Dissen L; Schemmel L; Middeke JM; Rücker V; Schreder M; Schetelig J; Bornhäuser M; Einsele H; Thiede C; Knop S
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1988-1996. PubMed ID: 27590108
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of multiple myeloma patients with isolated extramedullary relapse.
Qu XY; Chen LJ; Tian T; Duan LM; Lu RN; Lu H; Wu HX; Li JY
J Biomed Res; 2018 Jul; 32(4):264-269. PubMed ID: 28963446
[TBL] [Abstract][Full Text] [Related]
10. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
Bartel TB; Haessler J; Brown TL; Shaughnessy JD; van Rhee F; Anaissie E; Alpe T; Angtuaco E; Walker R; Epstein J; Crowley J; Barlogie B
Blood; 2009 Sep; 114(10):2068-76. PubMed ID: 19443657
[TBL] [Abstract][Full Text] [Related]
11. Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance.
Qu X; Chen L; Qiu H; Lu H; Wu H; Qiu H; Liu P; Guo R; Li J
Biomed Res Int; 2015; 2015():787809. PubMed ID: 25984534
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease.
Tucker SM; Zaihra T
Orbit; 2023 Dec; 42(6):603-611. PubMed ID: 36697375
[TBL] [Abstract][Full Text] [Related]
13. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
Weinstock M; Aljawai Y; Morgan EA; Laubach J; Gannon M; Roccaro AM; Varga C; Mitsiades CS; Paba-Prada C; Schlossman R; Munshi N; Anderson KC; Richardson PP; Weller E; Ghobrial IM
Br J Haematol; 2015 Jun; 169(6):851-8. PubMed ID: 25833301
[TBL] [Abstract][Full Text] [Related]
14. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.
Lee SE; Kim JH; Jeon YW; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Min CK
Ann Hematol; 2015 Mar; 94(3):445-52. PubMed ID: 25257340
[TBL] [Abstract][Full Text] [Related]
15. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.
Avivi I; Cohen YC; Suska A; Shragai T; Mikala G; Garderet L; Seny GM; Glickman S; Jayabalan DS; Niesvizky R; Gozzetti A; Wiśniewska-Piąty K; Waszczuk-Gajda A; Usnarska-Zubkiewicz L; Hus I; Guzicka R; Radocha J; Milunovic V; Davila J; Gentile M; Castillo JJ; Jurczyszyn A
Am J Hematol; 2019 Oct; 94(10):1132-1140. PubMed ID: 31334859
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
Usmani SZ; Mitchell A; Waheed S; Crowley J; Hoering A; Petty N; Brown T; Bartel T; Anaissie E; van Rhee F; Barlogie B
Blood; 2013 Mar; 121(10):1819-23. PubMed ID: 23305732
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
[No Abstract] [Full Text] [Related]
18. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases.
Rasche L; Bernard C; Topp MS; Kapp M; Duell J; Wesemeier C; Haralambieva E; Maeder U; Einsele H; Knop S
Ann Hematol; 2012 Jul; 91(7):1031-7. PubMed ID: 22286070
[TBL] [Abstract][Full Text] [Related]
19. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.
Waheed S; Mitchell A; Usmani S; Epstein J; Yaccoby S; Nair B; van Hemert R; Angtuaco E; Brown T; Bartel T; McDonald J; Anaissie E; van Rhee F; Crowley J; Barlogie B
Haematologica; 2013 Jan; 98(1):71-8. PubMed ID: 22733020
[TBL] [Abstract][Full Text] [Related]
20. Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients.
Yue X; He D; Zheng G; Yang Y; Han X; Li Y; Zhao Y; Wu W; Chen Q; Zhang E; Cai Z; He J
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
